Sitaman Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 13 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 2187.70%
- Profit Growth 306.31%
- Ebitda 59.13%
- Net Worth 308.26%
- Total Assets 154.93%
About Sitaman Pharmaceuticals
Sitaman Pharmaceuticals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 08 June 2011 and has a history of 13 years and eight months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Surendranath Upadhyay and Asha Upadhyay serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24233MH2011PTC218453
-
Company No.
218453
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
08 Jun 2011
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Sitaman Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Surendranath Upadhyay
|
Director | 08-Jun-2011 | Current |
|
Asha Upadhyay
|
Director | 08-Jun-2011 | Current |
Financial Performance of Sitaman Pharmaceuticals.
Sitaman Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 2187.7% increase. The company also saw a substantial improvement in profitability, with a 306.31% increase in profit. The company's net worth Soared by an impressive increase of 308.26%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sitaman Pharmaceuticals?
In 2021, Sitaman Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Sitaraman Hospitals Private LimitedSurendranath Upadhyay is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sitaman Pharmaceuticals?
Unlock and access historical data on people associated with Sitaman Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sitaman Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sitaman Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.